1159602-21-7

Basic information

• Product Name: 6-[3-(4-chloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-(1-methyl-1H-pyrazol-4-yl)-nicotinamide
• Synonyms: 6-[3-(4-chloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-(1-methyl-1H-pyrazol-4-yl)-nicotinamide
• CAS NO: 1159602-21-7
• Molecular Weight: 423.859
• Mol File: 1159602-21-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 6-[3-(4-chloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-(1-methyl-1H-pyrazol-4-yl)-nicotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-[3-(4-chloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-(1-methyl-1H-pyrazol-4-yl)-nicotinamide(1159602-21-7)
• EPA Substance Registry System: 6-[3-(4-chloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-(1-methyl-1H-pyrazol-4-yl)-nicotinamide(1159602-21-7)

Safety Data

• Hazardous Substances Data: 1159602-21-7(Hazardous Substances Data)

Upstream product

• 127426-56-6 [3-(4-chloro-phenyl)-5-methyl-isoxazol-4-yl]-methanol 
• 97026-71-6 (3-(4-chlorophenyl)-5-methyl)isoxazole-4-carboxylic acid ethyl ester 
• 28123-63-9 4-chlorobenzohydroximoyl chloride 
• 3848-36-0 4-chlorobenzaldoxime 
• 104-88-1 4-chlorobenzaldehyde 
• 456-48-4 3-Fluorobenzaldehyde 
• 1159251-38-3 [3-(3-fluoro-phenyl)-5-methyl-isoxazol-4-yl]-methanol 
• 917388-62-6 3-(3-fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester 
• 58606-42-1 N-hydroxy-3-fluoro-benzenecarboximidoyl chloride 
• 458-02-6 3-fluorobenzaldehyde oxime 
• 1159600-45-9 6-[3-(4-chloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinic acid methyl ester 
• 1159600-46-0 6-[3-(4-chloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinic acid 
• 69843-13-6 1-methyl-4-aminopyrazole 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS

The present invention relates to a process for the preparation of a compound of formula (I) which is useful as an intermediate in the preparation of active pharmaceutical compounds from a compound of formula (IV) wherein R1 and R2 ar

ISOXAZOLE-PYRIDINE DERIVATIVES

The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.